HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa-Reference-Cited by-同舟云学术

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa

Published:2017-06-01 Issue:2 Volume:75 Page:e45-e54
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Kityo Cissy,Thompson Jennifer,Nankya Immaculate,Hoppe Anne,Ndashimye Emmanuel,Warambwa Colin,Mambule Ivan,van Oosterhout Joep J.,Wools-Kaloustian Kara,Bertagnolio Silvia,Easterbrook Philippa J.,Mugyenyi Peter,Walker A. Sarah,Paton Nicholas I.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference29 articles.

1. Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review;Bhargava;J Int AIDS Soc.,2014

2. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings;Gilks;Lancet,2006

3. Assessment of second-line antiretroviral regimens for HIV therapy in Africa;Paton;N Engl J Med.,2014

4. Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period;Kyeyune;AIDS,2013

5. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool;Woods;J Clin Microbiol.,2012

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Etravirine Prevents West Nile Virus and Chikungunya Virus Infection Both In Vitro and In Vivo by Inhibiting Viral Replication;Pharmaceutics;2024-08-23

2. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial;The Lancet HIV;2024-03

3. Delayed identification of treatment failure causes high levels of acquired drug resistance and less future drug options among HIV-1-infected South Indians;Indian Journal of Medical Microbiology;2024-01

4. Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir‑era;Journal of Public Health in Africa;2023-11-22

5. Implementation of long-acting antiretroviral therapy in low-income and middle-income countries;Current Opinion in HIV and AIDS;2022-04-18